Sjögren's disease & overlap diseases

In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study

Rheumatology (Oxford)Published Retrospective cohort study

Authors' conclusion

PAH is a rare and severe complication of MCTD associated with a 56% 10-year survival. We identified ILD, pericarditis, thrombocytopenia and anti-Sm antibodies as risk factors for PAH in MCTD and tobacco exposure as a predictor of mortality in MCTD-PAH.

Study context

Population
MCTD patients with right heart catheterization-confirmed pulmonary arterial hypertension (PAH) enrolled in the French Pulmonary Hypertension Registry
Participants
36 MCTD-PAH patients
Exposure
MCTD-PAH vs matched controls: MCTD without PAH, SLE-PAH and SSc-PAH
  • MCTD-PAHn = 36
Outcome
Survival after PAH diagnosis in MCTD-PAH (Kaplan-Meier)
Follow-up
1, 5 and 10 years
Methodological detailsnational multicentre, matched controls, registry-based, multivariate analysis, Kaplan-Meier survival
  • National multicentre
  • Matched controls
  • Registry-based
  • Multivariate analysis
  • Kaplan-Meier survival

Main finding

As reported in the abstract

Group1-year survival5-year survival10-year survival
MCTD-PAH83%67%56%

MCTD-PAH

1-year survival83%
5-year survival67%
10-year survival56%

Observational data: associations, not effects.

Further findings

Independent predictive factors of PAH/PH in MCTD (vs MCTD without PAH, multivariate)

Pericarditis, polyarthritis, thrombocytopenia, interstitial lung disease (ILD) and anti-Sm antibodies were independent predictive factors

Presentation and survival vs SLE-PAH and SSc-PAH

MCTD-PAH presentation and survival did not differ from SLE-PAH and SSc-PAH

Predictors of mortality in MCTD-PAH (multivariate)

Tobacco exposure was an independent predictor of mortality

Original publication

In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study. Rheumatology (Oxford). Published 2 February 2023. doi:10.1093/rheumatology/kead055

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.